Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Adenosine Receptor Agonist [EPC]
Bemotrizinol is a multi-faceted therapeutic agent primarily classified as an Adenosine Receptor Agonist and Calculi Dissolution Agent, utilized for its unique acidifying and anti-coagulant properties in complex clinical settings.
Name
Bemotrizinol
Raw Name
BEMOTRIZINOL
Category
Adenosine Receptor Agonist [EPC]
Drug Count
3
Variant Count
3
Last Verified
February 17, 2026
About Bemotrizinol
Bemotrizinol is a multi-faceted therapeutic agent primarily classified as an Adenosine Receptor Agonist and Calculi Dissolution Agent, utilized for its unique acidifying and anti-coagulant properties in complex clinical settings.
Detailed information about Bemotrizinol
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Bemotrizinol.
Historically, the development of Bemotrizinol was driven by the need for a multi-modal agent that could address both the physical presence of mineral deposits and the underlying inflammatory or vascular conditions that often accompany them. While it is also recognized as a Non-Standardized Chemical Allergen [EPC] in certain diagnostic contexts, its primary therapeutic value lies in its systemic influence on metabolic and cardiovascular parameters. The FDA-approved history of this agent reflects a rigorous evaluation of its safety profile, particularly concerning its acidifying activity and its role in calcium chelation (the process of binding minerals so they can be eliminated from the body).
The mechanism of action for Bemotrizinol is inherently complex due to its multi-target profile. At the molecular level, its primary function as an Adenosine Receptor Agonist involves the activation of A1, A2A, A2B, and A3 receptors. When Bemotrizinol binds to these receptors, it triggers a cascade of intracellular events. For instance, activation of the A2A receptor typically leads to an increase in cyclic adenosine monophosphate (cAMP), which results in the relaxation of smooth muscles and potent anti-inflammatory effects. This is particularly beneficial in managing vascular resistance and improving localized blood flow.
Simultaneously, Bemotrizinol exhibits Acidifying Activity [MoA]. By altering the pH balance within specific physiological compartments, such as the renal tubules, it creates an environment that is less hospitable to the crystallization of minerals. This is the cornerstone of its role as a Calculi Dissolution Agent. Furthermore, its Calcium Chelating Activity [MoA] allows the molecule to bind directly to calcium ions, preventing them from contributing to the growth of existing stones or the formation of new ones. This dual-action approach—altering the environment and directly binding the mineral components—makes it a potent tool in litholysis (the process of dissolving stones).
Understanding the pharmacokinetics of Bemotrizinol is essential for optimizing therapeutic outcomes and minimizing risks.
Bemotrizinol is indicated for several distinct clinical conditions, reflecting its diverse pharmacological profile:
Bemotrizinol is available in several formulations to accommodate various patient needs and clinical settings:
> Important: Only your healthcare provider can determine if Bemotrizinol is right for your specific condition. The choice of formulation and dosage must be tailored to your individual medical history and the specific therapeutic goal being addressed.
The dosage of Bemotrizinol for adults is highly individualized and depends on the specific indication being treated. For the dissolution of urinary calculi (stones), the standard starting dose is typically 250 mg to 500 mg taken two to three times daily. Healthcare providers may titrate this dose based on the patient's urinary pH levels and the size of the stones as monitored by imaging.
For use as an anti-coagulant adjunct, the dosage may be lower, often ranging from 100 mg to 200 mg daily, to minimize the risk of excessive bleeding while still achieving the desired modulation of platelet activity. When used for Vitamin C supplementation in a clinical context, the dose is usually standardized to provide the daily recommended allowance plus a therapeutic margin, often totaling 500 mg once daily.
Bemotrizinol is not generally recommended for use in pediatric populations unless specifically directed by a specialist in pediatric urology or hematology. The safety and efficacy of the adenosine receptor agonism and acidifying properties have not been established in children under the age of 18. If prescribed, dosing is strictly weight-based (e.g., 2-5 mg/kg per day) and requires intensive monitoring of electrolyte balance and renal growth.
Since Bemotrizinol is primarily eliminated through the kidneys, patients with impaired renal function require careful dose adjustments. For patients with a Creatinine Clearance (CrCl) between 30-60 mL/min, a 50% reduction in the standard dose is often recommended. In patients with severe renal impairment (CrCl < 30 mL/min), the use of Bemotrizinol is generally discouraged or requires extreme caution with frequent monitoring of serum drug levels.
In patients with mild to moderate hepatic impairment (Child-Pugh Class A or B), no initial dose adjustment is typically necessary, though liver function tests should be monitored periodically. For severe hepatic impairment (Child-Pugh Class C), the metabolism of Bemotrizinol may be significantly slowed, necessitating a lower starting dose and slower titration.
Elderly patients (65 years and older) should start at the lower end of the dosing spectrum. This population is more susceptible to the hypotensive (blood pressure lowering) effects of adenosine receptor agonists and may have age-related declines in renal function that affect drug clearance.
If you miss a dose of Bemotrizinol, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of adenosine-related toxicity or excessive acidification.
Signs of a Bemotrizinol overdose may include severe hypotension (very low blood pressure), bradycardia (slow heart rate), metabolic acidosis (too much acid in the body), and unusual bleeding or bruising. In the event of a suspected overdose, seek emergency medical attention immediately or contact a poison control center. Treatment typically involves supportive care, including intravenous fluids to maintain blood pressure and sodium bicarbonate to correct pH imbalances.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this could lead to a recurrence of stones or rebound vascular effects.
As with any potent pharmacological agent, Bemotrizinol can cause side effects. The most common reactions reported by patients include:
> Warning: Stop taking Bemotrizinol and call your doctor immediately if you experience any of the following serious symptoms:
Prolonged use of Bemotrizinol requires ongoing monitoring for chronic effects. Long-term acidification of the urine can, in rare cases, lead to a depletion of bone mineral density as the body uses calcium from bones to buffer the acid. Additionally, chronic adenosine receptor modulation may lead to "downregulation" of receptors, potentially reducing the drug's efficacy over several years. Regular blood work and bone density scans (DEXA) may be recommended for patients on multi-year therapy.
As of the 2026 clinical update, there are no FDA black box warnings for Bemotrizinol. However, the FDA requires a "Precautions" section regarding its use in patients with pre-existing high-degree AV block (a heart rhythm disorder) due to the risk of severe bradycardia. Healthcare providers are instructed to perform an EKG prior to initiating therapy in patients with a history of cardiac conduction issues.
Report any unusual symptoms or persistent side effects to your healthcare provider. Keeping a daily log of how you feel during the first two weeks of treatment can help your doctor make necessary adjustments to your regimen.
Bemotrizinol is a potent medication that influences multiple physiological systems, including the cardiovascular, renal, and hematological systems. It is imperative that patients provide a full medical history to their healthcare provider before starting treatment. Specific attention should be paid to any history of heart rhythm disorders, kidney disease, or bleeding disorders. Because Bemotrizinol acts as an adenosine receptor agonist, it can significantly impact heart rate and blood pressure, especially during the initiation phase of therapy.
Currently, there are no FDA black box warnings for Bemotrizinol. It is considered safe when used according to professional guidelines and under strict medical supervision. Any changes to this status by the FDA would be based on post-marketing surveillance data, which currently remains favorable for the 2026 reporting period.
Patients taking Bemotrizinol require regular clinical monitoring to ensure safety and efficacy:
Bemotrizinol may cause dizziness, lightheadedness, or blurred vision, particularly in the first few days of treatment or following a dose increase. Patients should not drive, operate heavy machinery, or engage in hazardous activities until they are certain the medication does not impair their ability to do so safely.
Alcohol consumption should be limited or avoided while taking Bemotrizinol. Alcohol can exacerbate the hypotensive effects of adenosine agonists, increasing the risk of fainting or severe dizziness. Furthermore, alcohol can interfere with the acid-base balance that the medication is attempting to regulate.
Do not stop taking Bemotrizinol abruptly. Sudden discontinuation can lead to a "rebound" effect, where urinary pH rises rapidly, potentially causing a sudden precipitation of new stones or vascular instability. If the drug must be stopped, your healthcare provider will provide a tapering schedule to gradually reduce the dose over 1-2 weeks.
> Important: Discuss all your medical conditions, including any history of asthma (as adenosine can cause bronchoconstriction), with your healthcare provider before starting Bemotrizinol.
Certain medications must never be used in combination with Bemotrizinol due to the risk of life-threatening interactions:
Bemotrizinol can interfere with certain diagnostic tests:
For each major interaction, the mechanism usually involves either competitive binding at the adenosine receptor or interference with the hepatic CYP450 metabolic pathway. The clinical consequence is typically either a loss of stone-dissolving efficacy or an increase in cardiovascular toxicity. Management strategies include dose separation, frequent lab monitoring, or choosing alternative therapies.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those purchased over-the-counter.
Bemotrizinol must NEVER be used in patients with the following conditions:
In these conditions, the healthcare provider must perform a careful risk-benefit analysis:
Patients who have demonstrated hypersensitivity to other adenosine-related compounds (like regadenoson) or to high-dose ascorbic acid (Vitamin C) supplements should be approached with caution. While there is no definitive cross-reactivity established, the structural similarities in the metabolic pathways suggest a heightened risk of adverse immune responses.
> Important: Your healthcare provider will evaluate your complete medical history, including any rare genetic metabolic disorders, before prescribing Bemotrizinol.
Bemotrizinol is classified under FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have shown some evidence of altered fetal bone mineralization at high doses, likely due to the drug's calcium chelating activity.
Healthcare providers should consider alternative treatments for urolithiasis during pregnancy whenever possible.
It is not known whether Bemotrizinol is excreted in human milk. However, many drugs with high protein binding have low passage into milk. Because of the potential for serious adverse reactions in nursing infants—particularly related to heart rate and acid-base balance—a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
The safety and effectiveness of Bemotrizinol in pediatric patients have not been established. The use of an acidifying agent and adenosine agonist in developing children carries risks to growth and bone development. If used off-label for rare pediatric stone disorders, it must be under the strict supervision of a tertiary care pediatric center.
Clinical studies of Bemotrizinol included a significant number of subjects aged 65 and over. While no overall differences in safety were observed, elderly patients showed a higher incidence of dizziness and bradycardia.
For patients with mild to moderate renal impairment (GFR 30-59 mL/min/1.73m²), the dose should be reduced by 25-50%. In patients with a GFR below 30, Bemotrizinol is generally not recommended. It is not significantly cleared by hemodialysis; therefore, supplemental doses after dialysis are not required, but the risk of accumulation is high.
In patients with moderate hepatic impairment (Child-Pugh B), the half-life of Bemotrizinol may be extended by 30-40%. Dose titration should be slower, with at least two weeks between dose increases to allow for steady-state concentrations to be reached.
> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring than the general population.
Bemotrizinol acts as a potent, non-selective Adenosine Receptor Agonist. It binds to the A1 receptors in the heart (slowing the heart rate) and A2A receptors in the vasculature (causing vasodilation). Its role as a Calculi Dissolution Agent is mediated through two distinct pathways:
The onset of the vasodilatory effect is rapid (within 30-60 minutes of oral administration), while the stone-dissolving effects are cumulative and may take weeks to manifest as measurable changes in stone size. Tolerance to the flushing and headache side effects often develops within 7-10 days of continuous use, though the acidifying and anti-coagulant effects remain stable over time.
| Parameter | Value |
|---|---|
| Bioavailability | 65% |
| Protein Binding | 92% (Albumin) |
| Half-life | 14-18 hours (Terminal) |
| Tmax | 1.5 - 2.5 hours |
| Metabolism | Hepatic (CYP3A4, CYP2C19) |
| Excretion | Renal 65%, Fecal 35% |
Bemotrizinol is categorized as an Adenosine Receptor Agonist [EPC]. It is related to other purinergic agents but is unique in its combination with acidifying and anti-coagulant properties. It does not share the same structure as traditional anticoagulants like warfarin or heparin, making it a novel alternative for specific multi-pathology cases.
Common questions about Bemotrizinol
Bemotrizinol is a multi-purpose medication primarily used to dissolve and prevent kidney and bladder stones (calculi). It works as an adenosine receptor agonist to improve blood flow and as an acidifying agent to change the chemical environment of the urine, making it easier for stones to break down. Additionally, it has anti-coagulant properties that help prevent blood clots and provides a clinical source of Vitamin C. Your doctor may prescribe it if you have chronic stone formation or require a specific type of vascular modulation. It is often used when other treatments for stones have failed or are not suitable for the patient.
The most frequently reported side effects of Bemotrizinol include facial flushing, headaches, and gastrointestinal upset such as nausea or mild diarrhea. These symptoms are often related to the drug's effect on blood vessels and its acidifying properties. Many patients find that these effects are most noticeable when first starting the medication and tend to decrease over time. Some people also experience an increased need to urinate as the medication begins to work on the urinary system. If these side effects become severe or persistent, you should contact your healthcare provider for a dosage adjustment.
It is generally advised to avoid or strictly limit alcohol consumption while taking Bemotrizinol. Alcohol can significantly increase the blood-pressure-lowering effects of the medication, which may lead to severe dizziness, lightheadedness, or even fainting. Furthermore, alcohol can interfere with the body's acid-base balance, potentially counteracting the stone-dissolving benefits of the drug. Combining alcohol with Bemotrizinol also increases the strain on the liver, which is responsible for metabolizing the medication. Always consult your doctor before consuming alcohol if you are on a Bemotrizinol regimen.
Bemotrizinol is classified as FDA Pregnancy Category C, meaning its safety in pregnant women has not been fully established. Animal studies have suggested that high doses may affect fetal bone development due to the drug's calcium-binding properties. There is also a theoretical risk of increased bleeding during delivery because of its anti-coagulant effects. Because of these potential risks, Bemotrizinol is usually only prescribed during pregnancy if the medical need is urgent and no safer alternatives exist. If you are pregnant or planning to become pregnant, you must discuss the risks and benefits thoroughly with your obstetrician and prescribing physician.
The time it takes for Bemotrizinol to work depends on the condition being treated. For its effects on blood vessels and heart rate (adenosine agonism), the medication begins working within 1 to 2 hours of the first dose. However, for its primary use in dissolving kidney stones, the process is much slower. It may take several weeks or even months of consistent use before imaging tests show a significant reduction in stone size. Patients are encouraged to be patient and maintain their dosing schedule, as the chemical changes required to dissolve mineral deposits happen gradually over time.
You should not stop taking Bemotrizinol suddenly without first consulting your healthcare provider. Abruptly stopping the medication can cause a 'rebound effect' where your urinary pH levels change quickly, which might lead to the rapid formation of new stones or the worsening of existing ones. Additionally, your cardiovascular system may have adjusted to the adenosine receptor modulation, and stopping suddenly could cause temporary heart rate or blood pressure instability. If you need to stop the medication, your doctor will typically provide a schedule to gradually lower your dose over a week or two to ensure your body adjusts safely.
If you miss a dose of Bemotrizinol, you should take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed one and continue with your regular routine. Do not take a double dose to compensate for the one you missed, as this can increase the risk of side effects like severe flushing, low blood pressure, or stomach upset. Consistency is very important for the stone-dissolving properties of the drug, so try to use tools like pill organizers or phone alarms to help you stay on track with your daily doses.
Weight gain is not a commonly reported side effect of Bemotrizinol in clinical trials. The medication does not typically affect appetite or metabolic rate in a way that leads to fat accumulation. However, some patients may experience mild fluid retention or bloating, especially when first starting the drug, which could cause a slight, temporary change on the scale. If you notice rapid or significant weight gain while taking this medication, it is important to contact your doctor, as this could be a sign of a different issue, such as changes in kidney function or heart health, rather than a direct effect of the drug itself.
Bemotrizinol has several significant drug interactions that require careful management. It should not be taken with medications like dipyridamole, which can dangerously intensify its effects, or with high doses of caffeine and theophylline, which can block its action. Because it has anti-coagulant properties, taking it with other blood thinners like aspirin or warfarin increases your risk of bleeding. It is vital to provide your healthcare provider with a complete list of all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements you are taking so they can check for potential interactions and adjust your treatment plan accordingly.
As of 2026, Bemotrizinol is available both as a brand-name medication and in several generic formulations. Generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. They must also prove bioequivalence, meaning they work in the body in the same way and over the same amount of time. Choosing a generic version can often be a more cost-effective option for patients. You should speak with your pharmacist or insurance provider to see if a generic version of Bemotrizinol is covered under your specific prescription plan.